about
Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activationMineralocorticoid receptor antagonists: emerging roles in cardiovascular medicineThe ubiquitous mineralocorticoid receptor: clinical implicationsRapid steroid hormone actions initiated at the cell surface and the receptors that mediate them with an emphasis on recent progress in fish modelsMinireview: aldosterone biosynthesis: electrically gated for our protectionPhysiological partial aldosterone resistance in human newborns.Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors.Aldosteronism and resistant hypertension.Aldosterone postnatally, but not at birth, is required for optimal induction of renal mineralocorticoid receptor expression and sodium reabsorption.Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome.Diverse immunostaining patterns of mineralocorticoid receptor monoclonal antibodies.Aldosterone induces elastin production in cardiac fibroblasts through activation of insulin-like growth factor-I receptors in a mineralocorticoid receptor-independent manner.Hippocampal formation: shedding light on the influence of sex and stress on the brainThe mineralocorticoid receptor: insights into its molecular and (patho)physiological biologyVisceral adipose tissue: emerging role of gluco- and mineralocorticoid hormones in the setting of cardiometabolic alterationsThe pharmacological treatment of primary aldosteronism.Why are mineralocorticoid receptor antagonists cardioprotective?Aldosterone-to-Renin Ratio Is Associated With Reduced 24-Hour Heart Rate Variability and QTc Prolongation in Hypertensive PatientsLow-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat.Endocrine and hypertensive disorders of potassium regulation: primary aldosteronismMineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat.Aldosterone, C-reactive protein, and plasma B-type natriuretic peptide are associated with the development of metabolic syndrome and longitudinal changes in metabolic syndrome components: findings from the Jackson Heart StudyImmunohistochemical demonstration of the mineralocorticoid receptor, 11beta-hydroxysteroid dehydrogenase-1 and -2, and hexose-6-phosphate dehydrogenase in rat ovary.Circulating aldosterone induces the apical accumulation of the proton pumping V-ATPase and increases proton secretion in clear cells in the caput epididymis.Aldosterone induces rapid sodium intake by a nongenomic mechanism in the nucleus tractus solitariusMineralocorticoid receptors and the heart, multiple cell types and multiple mechanisms: a focus on the cardiomyocyte.Vascular effects of aldosterone: sorting out the receptors and the ligands.4-Hydroxychalcone attenuates hyperaldosteronism, inflammation, and renal injury in cryptochrome-null mice.Differential regulation of H+-ATPases in MDCK-C11 cells by aldosterone and vasopressin.Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model.Rapid effects of aldosterone on clonal human vascular smooth muscle cells.Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathwayTreatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension.Effect of aldosterone and its antagonist on the expression of PAI-1 and TGF-β1 in rat hepatic stellate cells.Aldosterone to active renin ratio is associated with nocturnal blood pressure in obese and treated hypertensive patients: the Styrian Hypertension Study.Aldosterone increases cardiac vagal tone via G protein-coupled oestrogen receptor activation.Electrophysiological responses of sympathetic preganglionic neurons to ANG II and aldosterone.EF domains are sufficient for nongenomic mineralocorticoid receptor actions.Impact of Adrenal Steroids on Regulation of Adipose Tissue.
P2860
Q24294309-16642370-F535-41C5-B8D6-8E25DEE424A3Q26827202-F5FBCDCD-BA91-40C8-9054-5464B3385597Q26861721-DD0E5E0A-637A-488A-B9D0-2A92A8AF8CCEQ26866051-AEF933D6-A58A-404E-A718-9B2535A09532Q30417879-7C3F24B5-83F7-4E0D-B555-70246F779303Q34057569-75557D75-F81C-460B-A345-5D0021DFBB98Q34152478-0535D977-A0E4-4BF7-8FA3-9244456D80EDQ34557307-17A4499F-FDEA-4974-ADD5-2A0E1F546B6AQ35001362-5A97D1BB-D25A-4F7E-B16C-233111140529Q35113885-33E18E7F-5419-4D52-8B33-A58642D97B6CQ35552530-7B0F7770-2707-41B1-97BF-2A9B201F3F2EQ35963179-26F39C86-6D47-49BF-985D-F1CB47C7B946Q36180252-BB148F4D-A0B0-4832-AA14-9E692B38A519Q36238325-3E0B10D8-5949-4C97-906F-50CACF8C1ED8Q36297722-4D9FB35A-0756-491E-AB98-8D69F6F8A272Q36428495-AFE0C899-E31E-4EA5-BFFA-385D0167D6FDQ36639935-465EC1E1-2A64-4AA1-8948-606A8487F1E0Q36653580-46B2D5E4-897F-4E3D-B4A5-DD057AFB8452Q36805476-8EB29AE0-D329-408E-9692-F54F0D440D25Q37107686-40975494-8DDF-4F05-95FF-B99F0596C063Q37190283-665D93ED-DE48-499E-8357-C0841FF3B0DCQ37193640-E1F6C007-558F-4B39-9C0C-5BCCA2D8EAEFQ37234861-E96BE2CD-B0E5-49A0-91EC-EA8DC60CBDBEQ37476423-492F6874-6CE7-4FB4-B088-5E2590875BCEQ37487356-E10634CB-804E-4D56-8D4E-68A1BC854612Q38119546-12CCE6DA-A3BD-4444-9363-52397C31E5FAQ38125527-E138381D-83C9-4A1D-8131-2C6DB58B7958Q39163006-FD6E499F-930B-4BB7-A56F-2EC532711044Q39793078-4488C063-CA7D-433F-A387-F7688A57AA47Q40000499-66992268-7651-4557-AF95-BF1AF3F75169Q40232321-8F7ECB7D-58D6-438F-BC8F-3F6AAF79146CQ41874135-D542AF6D-07B4-4CEE-A48C-DA5F7875B745Q42046045-AB3B07D4-C396-42CA-BBBE-EEB541C524FEQ42467860-826F2355-1CA4-454B-9B94-E9B0387849E6Q43120182-1CAD26F9-9865-4BB2-B072-3EC46B40D369Q43445481-3FF74783-4EA7-4698-A431-939E9CB1FB60Q43639675-DC658058-8F98-4A48-90CD-B707A9B8FBEFQ45954125-61B3CB0A-ADDB-422D-99A2-2F8D45E03222Q46815869-E292AD5D-DD9B-4071-BE22-E4467CD863ECQ50068164-24C63CAD-2D2B-4F6B-AF55-BDB6B89E567B
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The nongenomic actions of aldosterone.
@ast
The nongenomic actions of aldosterone.
@en
The nongenomic actions of aldosterone.
@nl
type
label
The nongenomic actions of aldosterone.
@ast
The nongenomic actions of aldosterone.
@en
The nongenomic actions of aldosterone.
@nl
prefLabel
The nongenomic actions of aldosterone.
@ast
The nongenomic actions of aldosterone.
@en
The nongenomic actions of aldosterone.
@nl
P356
P1433
P1476
The nongenomic actions of aldosterone.
@en
P2093
John W Funder
P304
P356
10.1210/ER.2005-0004
P577
2005-04-06T00:00:00Z